Core Viewpoint - The inclusion of cochlear implants in the medical insurance reimbursement scope is expected to significantly benefit the company’s cochlear implant business and the overall market demand in China [2] Group 1: Company Performance - On January 26, 2026, the company’s stock closed at 32.18 yuan, down 5.46%, with a turnover rate of 4.83%, a trading volume of 180,300 shares, and a transaction amount of 596 million yuan [1] Group 2: Market and Business Impact - The incidence rate of congenital deafness in newborns is approximately 2‰-3‰, indicating a substantial market potential for cochlear implants in China, which currently has a low market penetration rate [2] - The policy change to include cochlear implants in medical insurance will alleviate the financial burden on families with hearing-impaired children, effectively releasing actual market demand in China [2] - The company is actively pursuing a global expansion strategy, particularly in Europe, to enhance local service capabilities and improve supply chain resilience [2]
股市必读：美好医疗（301363）1月26日董秘有最新回复